SAN DIEGO, CA--(Marketwire - January 22, 2010) - Entest BioMedical Inc. (OTCBB: ENTB)announced that it has acquired the first of several photoceutical devicesit will be using in the development of its proprietary laser device,ENT-576. This laser device will be used in conjunction with stem celltherapy to enhance efficacy in the regenerative treatment of ChronicObstructive Pulmonary Disease (COPD).
The Company’s Chairman & CEO David Koos stated, “We are excited with thisfirst step in moving towards a specialized laser device that will augmentstem cell therapy for treating COPD. We believe the ENT-576 can beutilized to ‘paint’ damaged lung tissue with laser irradiation allowingstem cells therapeutic treatment to ‘spot focus’ on the damaged tissueresulting in not only a reduction of progression but also an actualreversal of the effects of COPD.”
A spokesperson for Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) notedthat it is anticipated this research will start up shortly at its 15,000sq. ft. stem cell research facility. The projected outcomes of this studywill be the development of ENT-576, a specialized laser device, as well asan effective stem cell therapy for treating COPD.
COPD is the 4th leading cause of death in the United States and there iscurrently no known cure.
About Entest BioMedical Inc.:
Entest BioMedical Inc. (OTCBB: ENTB) is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease(COPD), immuno-cancer therapies, testing procedures for diabetes, stem cellresearch applications for diabetes and other illnesses. The Company also isinvolved with medical device development (including stem cell extractioninstrumentation). ENT-576 is a proprietary laser device currently underdevelopment by Entest. The Company has filed 3 patent applicationsrelating to the treatment of COPD.
About Bio-Matrix Scientific Group:
Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is the majority owner ofEntest BioMedical Inc. BMSN is a biotechnology company headquartered inSan Diego, Ca. with a 15,000 sq. ft. facility that houses two securecryogenic stem cell banks, three research laboratories, asepticcellular/tissue class 10,000/100 processing lab, hematology, microbiologyand flow cytometry laboratories. David Koos serves as Chairman & CEOconcurrently for BMSN and ENTB.
Forward-looking statements:
This news release may contain forward-looking statements. Forward-lookingstatements are inherently subject to risks and uncertainties, some of whichcannot be predicted or quantified. Future events and actual results coulddiffer materially from those set forth in, contemplated by, or underlyingthe forward-looking statements. The risks and uncertainties to whichforward-looking statements are subject include, but are not limited to, theeffect of government regulation, competition and other material risks.
Follow the Company’s progress on Twitter:
http://twitter.com/Entest_BioMed
Contact:
David R. Koos
Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax
Entest BioMedical Inc.
Email Contact
www.EntestBio.com
Bio-Matrix Scientific Group Inc.
www.BMSN.us
Email Contact
